RT Journal Article
SR Electronic
T1 #288 Prognostic factors following cytoreductive surgery for advanced epithelial ovarian cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A267
OP A268
DO 10.1136/ijgc-2023-ESGO.554
VO 33
IS Suppl 3
A1 Lamela, Ester Martínez
A1 Vílchez, Jesús Molero
A1 Gómez, Angela santiago
A1 Aguado, Judith Suarez
A1 Lucena, Yolanda Expósito
YR 2023
UL http://ijgc.bmj.com/content/33/Suppl_3/A267.abstract
AB Introduction/Background To examine the association between clinicopathological factors and survival in advanced epithelial ovarian, tubal, and primary peritoneal cancers patients (stages III-IV FIGO 2017) who had primary cytoreductive surgery (PDS) and those that received neoadjuvant platinum-based chemotherapy (NAC) followed by interval debulking surgery (IDS).Methodology 75 women were recruited in this study who had PDS or IDS between January 2008-March 2023. Association between clinical characteristics, pretreatment imaging, serum markers, surgical and pathological factors, and disease recurrence and overall survival was examined in univariable and multivariable analysis (Kaplan-Meier and Cox proportional hazard model).Results 47 women (PDS) and 28 (IDS) women were included. No residual tumor (R0) was in 72.3% of patients after PDS and in 57.2% of patients after IDS. Postoperative rates of adverse effects and mortality were higher after PDS than after IDS (p=0.793). Median overall survival was not reached for the PDS group and 78 months for the IDS group (p=0.292). Median progression-free survival was 60 months in the PDS group and 52 months in the IDS group (p=0.04). Factors in multivariable analysis associated with increased risk of recurrence included primary peritoneal carcinoma (hazard ratio HR: 6.09, 95% CI 1.55–23.87, p= 0.01), residual tumor >1cm (HR: 2.72, 95% CI 1.06–6.98, p= 0.037) and stable/progression in response to chemotherapy (HR 8.85, 95% CI 1.76–44.45, p= 0.008).Conclusion PDS before chemotherapy is the standard of care for patients with advanced ovarian cancer. NAC appeared to be a good option when the PDS is not likely as a first choice. The worse survival outcome was associated with primary peritoneal carcinoma, residual tumor in surgical status and a bad response to chemotherapy.Abstract #288 Figure 1 Disclosures Factors independently associated with increased risk of death included residual tumor>1 cm (HR: 4.52, 95% CI 1.86–11.02, p= 0.001) and stable disease/progression at chemotherapy (HR: 13.42, 95% CI 2.7–66.57, p= 0.001)